Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Pharmacol Ther. 2020 Oct 20;219:107709. doi: 10.1016/j.pharmthera.2020.107709

Table 3A.

Clinical trials of CD40 agonist therapy

Drug Feature Phase Disease Outcome PMID/Identifier
CP-870,893 Human mAb 1 Solid tumors Safe; Effective 17327609
1 Advanced solid tumor Safe; Little efficiency 20855968
1 Advanced pancreatic ductal adenocarcinoma Safe a; Effective 23983255
21436454
1b Malignant pleural mesothelioma Safeb 26386124
1 Metastatic melanoma Safe c; Effective 30288340
Dacetuzumab Humanized mAb 1 Refractory NHL Safe; Effective 19636010
1 CLL Safe; Little efficiency 20038235
1 Advanced MM Safe; Little efficiency 20133895
Relapsed DLBCL Safe d; Effective 22775314
2 Relapsed DLBCL Safe; Effective 24919462
2b Relapsed DLBCL Safe e; Not effective 25651427
ChiLob 7/4 Chimeric mAb 1 CD40-expressing solid tumors and DLBCL Safe; Little efficiency 25589626
ADC-1013 Human mAb 1 Advanced solid tumors Safe 30664811
Selicrelumab Human mAb 1 Solid tumors Unpublished NCT02665416
1 Refractory B-cell NHL Ongoing NCT03892525
APX005M Humanized mAb 1 Solid tumors Not reported NCT02482168
1/2 NSCLC& melanoma Ongoing NCT03123783
2 Rectal adenocarcinoma Ongoing NCT04130854
2 Soft tissue sarcoma Ongoing NCT03719430
2 Melanoma Ongoing NCT04337931
NCT02706353
1 Pediatric central nervous system tumors Ongoing NCT03389802
SEA-CD40 Humanized mAb 1 Carcinoma Ongoing NCT02376699
CDX-1140 Human mAb 1 Carcinoma Ongoing NCT04364230
1 Advanced malignancies Ongoing NCT03329950
2141-V11 Fc-engineered human mAb 1 Solid tumor & cancer of skin Ongoing NCT04059588
NG-350A Ad-human CD40 mAb 1 Metastatic cancer & epithelial Tumor Ongoing NCT03852511
BPX101 Autologous DC transduced with Ad-human CD40 1 Metastatic castration-resistant prostate cancer Safe; Effective 28608115

Abbreviations: Ad-human mAb, adenovirus carrying agonistic human CD40 mAb gene; Ad-human CD40, adenovirus carrying human CD40 gene; CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; Fc, constant fragment; mAb, monoclonal antibody; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer.

a

in combination with gemcitabine;

b

in combination with cisplatin & pemetrexed;

c

in combination with tremelimumab;

d

in combination with rituximab & gemcitabine;

e

in combination with R-ICE (rituximab, ifosfamide, carboplatin and etoposide).